UK PNH diagnosis takes just 6-12 months through Leeds, yet 30% of the ~600 tracked patients also have aplastic anaemia.

PNH is a clonal haematopoietic stem cell disorder caused by somatic PIG-A mutation, producing GPI-anchor deficiency and complement-mediated red blood cell lysis. The Leeds National PNH Service runs the UK's single national registry: approximately 600 patients on complement inhibitor therapy, plus 100 to 150 additional patients with small PNH clones monitored without treatment. Annual new UK diagnoses run 50 to 70, with a median age at diagnosis of 38 to 42 years and an equal gender distribution across the tracked cohort.

UK PNH survival on complement inhibitor therapy now approaches that of the general population, a landmark outcome for a historically fatal disease. Around 30% of UK PNH patients have concurrent aplastic anaemia features requiring dual management: complement inhibitor alongside immunosuppressive therapy, eltrombopag, or a bone marrow transplant discussion, coordinated through the Leeds multidisciplinary service and 15 JACIE-accredited NHS BMT centres across the country.

Nearly a third of UK PNH patients need dual disease management.

Five questions this report answers:

Q1 - What is the size of the NHS-commissioned PNH population against the pending iptacopan decision?

Q2 - Why does the UK achieve a materially shorter PNH time-to-diagnosis than other markets?

Q3 - How does the 30% PNH-aplasia overlap population get managed within the NHS?

Q4 - What does the pending iptacopan NICE decision mean for UK PNH access?

Q5 - How many UK PNH patients are monitored on the Leeds registry without active treatment?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#PNH #NHS #NICE #RareDisease #UKHealthcare #DiseaseLandscape

Live report page:  https://axlrx.ai/pnh/uk/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-                    hello@axlrx.ai

Web-                    https://axlrx.ai/

Germany's own DGHO guideline admits it has no national PNH data, borrowing 16 cases per million from UK and France.

PNH is a clonal haematopoietic stem cell disorder caused by somatic PIG-A mutation, producing GPI-anchor deficiency and complement-mediated red blood cell lysis. Diagnosis requires GPI-anchor flow cytometry showing deficient or reduced expression of at least two GPI-anchored markers across at least two cell lineages, typically granulocytes and reticulocytes. In Germany, that testing and the resulting patient population concentrate almost entirely at two institutions: the German PNH-Register, housed at Ulm's Institute for Clinical Transfusion Medicine and Immunogenetics, and the West German Cancer Center at University Hospital Essen. Both feed patients into the International PNH Registry, the same dataset underpinning the long-term ravulizumab and eculizumab outcomes literature.

The DGHO's own Onkopedia clinical guideline, the reference document German haematologists use, states directly that Germany-specific prevalence and incidence figures do not exist. In their place, it extrapolates an estimated 16 cases per million and 1.3 new diagnoses per million annually from British and French registry data. That borrowed-estimate approach has a direct commercial consequence: any epidemiology-based market sizing for a new PNH therapy launching in Germany inherits the uncertainty of a foreign-registry extrapolation rather than a domestic count, and the two-centre referral concentration means patient-finding runs through a narrower institutional funnel than in markets with broader registry infrastructure.

Germany's own guideline runs on borrowed numbers, not a domestic patient count.

Five questions this report answers:

Q1 - Why does Germany's own clinical guideline say national PNH prevalence data doesn't exist?

Q2 - Where does PNH diagnosis and care concentrate in Germany, and what does that mean for patient-finding?

Q3 - What diagnostic criteria confirm a PNH case in the German clinical pathway?

Q4 - What prevalence and incidence estimate does the DGHO Onkopedia guideline borrow from UK and France?

Q5 - Which two German institutions feed patient data into the International PNH Registry?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#PNH #Germany #DGHO #RareDisease #DiseaseLandscape #HematologyMarket

Live report page:  https://axlrx.ai/pnh/germany/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-                    hello@axlrx.ai

Web-                    https://axlrx.ai/

Fewer than 15 GCC labs run FLAER flow cytometry, holding confirmed PNH cases below 400 against 2,000-3,000 estimated patients.

Paroxysmal nocturnal hemoglobinuria is a clonal haematopoietic stem cell disorder caused by an acquired somatic PIG-A mutation, producing GPI-anchor-deficient blood cells vulnerable to complement-mediated lysis. Across the GCC, an estimated 2,000 to 3,000 patients carry PNH clones large enough to be clinically significant, but only around 400 are confirmed in NPHC and specialist haematology registries. The gap reflects both near-zero community disease awareness outside haematology and a consanguinity rate of 25% to 50% across Gulf populations, which raises the likelihood that a somatic PIG-A mutation acquires clinical significance against a background of higher underlying immune and clonal stress.

The standard PNH diagnostic panel, FLAER flow cytometry plus CD55/CD59, is available at fewer than 15 laboratories across the six GCC states. Most peripheral hospitals either refer samples internationally or fall back on CD55/CD59-only testing, which carries a 20% to 30% false-negative rate for small-clone PNH. Confirmed diagnosis concentrates at specialist centres such as KFSH&RC, which anchors the region's largest published PNH case series. Median time to diagnosis for symptomatic GCC patients runs two to four years, and disease often surfaces first as Budd-Chiari syndrome or aplastic anaemia; PNH-aplasia overlap accounts for 25% to 30% of GCC PNH cases against roughly 15% globally.

A lab-access gap, not disease rarity, hides most GCC PNH patients.

Five questions this report answers:

Q1 - What is the true size of the undiagnosed GCC PNH population, and where does it concentrate?

Q2 - Which GCC laboratories run FLAER flow cytometry, and what does that mean for time-to-treatment?

Q3 - What does compassionate-access-only status mean for near-term GCC uptake of iptacopan?

Q4 - What diagnostic and access barriers define the addressable GCC PNH market?

Q5 - Why does PNH often first present as Budd-Chiari syndrome or aplastic anaemia in the GCC?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#PNH #RareDisease #GCCHealthcare #Haematology #DiseaseLandscape #SFDA

Live report page:  https://axlrx.ai/pnh/gcc/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-                    hello@axlrx.ai

Web-                    https://axlrx.ai/

France's own hospitalization database puts 2022 PNH prevalence near 1 in 94,000, below Germany's borrowed 16-per-million figure.

A 2025 real-world study drawn from France's national hospitalization database, PMSI, accessed via the CASD secure data platform and funded by Roche France, identified 897 PNH patients between 2018 and 2022, with the annual count rising from 581 to 725 and roughly 100 newly diagnosed patients added each year. That translates to a 2022 prevalence near 1 in 94,000, below the 1-in-70,000-to-80,000 range Orphanet and France's national rare disease plan had assumed. The same cohort shows 55.3% of patients on a C5 inhibitor, with eculizumab accounting for 89.9% of new treatment starts and ravulizumab 10.1%. This is one of the few PNH cohorts in Europe built entirely from administrative hospital records rather than a clinician-reported registry.

For commercial teams, the discrepancy is the finding: Germany's DGHO Onkopedia guideline borrows a PNH prevalence of 16 cases per million from UK and French registries, yet France's own current hospital-database figure, 897 patients against a population of roughly 68 million, near 10.6 per million, comes in lower. France also runs diagnostic infrastructure other countries reference, a French National Observatory of PNH Clones sitting on an inter-laboratory flow-cytometry harmonization programme spanning more than 50 French-speaking centres since 2010. A market-sizing exercise anchored only on the literature-cited 16-per-million figure will overstate the addressable French population relative to what the country's own administrative data now shows.

France's own data undercuts the very prevalence figure Germany borrows from it.

Five questions this report answers:

Q1 - How big is France's treatable PNH population versus the literature estimate used elsewhere in Europe?

Q2 - Which centres actually see and diagnose PNH patients across France?

Q3 - How long does it take a French patient to reach a confirmed PNH diagnosis?

Q4 - What share of France's PNH cohort is on eculizumab versus ravulizumab today?

Q5 - How many French-speaking centres participate in the flow-cytometry harmonization programme behind France's PNH Observatory?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#PNH #France #PMSI #RareDisease #DiseaseLandscape #HematologyMarket

Live report page:  https://axlrx.ai/pnh/france/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-                    hello@axlrx.ai

Web-                    https://axlrx.ai/

41.9% of US adults meet the obesity threshold, but comorbidity segments, not the headline count, decide who gets covered.

Obesity is a chronic, relapsing metabolic disease defined by a body-mass index of 30 or greater. CDC NHANES data put US adult obesity prevalence at 41.9%, roughly 100 million adults, with severe obesity (BMI 40 or above) affecting 9.2%, about 22 million people. The most recent NHANES cycle shows age-adjusted obesity at 40.3% and severe obesity at 9.7%, up from 30.5% in 1999-2000. The disease stratifies into Class I (30-34.9), Class II (35-39.9), and Class III or severe (40 and above), each carrying a different comorbidity load and a different treatment and coverage rationale.

The clinical case for treatment now rests on outcomes, not weight alone. Two GLP-1 agents dominate: semaglutide 2.4mg (Wegovy, Novo Nordisk) delivered 15.3% weight loss in the STEP 1 trial, while tirzepatide (Zepbound, Eli Lilly) delivered 20.9% at its 15mg dose in SURMOUNT-1, a clear head-to-head efficacy gap. The SELECT trial then showed semaglutide cut major adverse cardiovascular events by 20% in adults with obesity and established cardiovascular disease but without diabetes, converting obesity from a cosmetic indication into a cardiovascular one. That evidence reframes the addressable population around comorbidity-defined segments that payers and Medicare will actually fund.

BMI alone no longer decides who gets treated or who gets paid for.

Five questions this report answers:

Q1 - How does the US obesity population stratify by BMI class and comorbidity?

Q2 - How does GLP-1 head-to-head efficacy in obesity map to patient segmentation?

Q3 - How large is the comorbidity-linked population anchoring obesity coverage, CVD and type 2 diabetes?

Q4 - How many US adults have obesity, and how is severe obesity defined?

Q5 - Which obesity segment opened Medicare coverage, and why does comorbidity outweigh BMI alone?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#Obesity #GLP1 #Cardiometabolic #USHealthcare #DiseaseLandscape

Live report page:  https://axlrx.ai/obesity/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-                    hello@axlrx.ai

Web-                    https://axlrx.ai/

NSCLC splits into five biomarker-defined segments, and 51% of US patients are diagnosed only after the disease reaches distant stage.

Non-small cell lung cancer is not one disease to size. Adenocarcinoma accounts for roughly 40% of all lung cancers, squamous cell carcinoma for 25 to 30%, and large cell carcinoma for about 10%. Within that histology map sits the segmentation that actually drives treatment: EGFR, ALK, ROS1, KRAS G12C, and PD-L1 expression tier, each carrying a different first-line standard of care, and sizing the wrong one is the most common pre-launch error. The US will see an estimated 229,410 new lung cancer diagnoses in 2026, and non-small cell histology accounts for roughly 85% of them.

Fifty-one percent of cases present at distant stage against just 24% localized, based on SEER 2016-2022 diagnosis data, and the biomarker-driven segment map only helps a patient whose disease is caught before it reaches that point. EGFR, ALK, KRAS G12C, and PD-L1 prevalence vary meaningfully across US and North American cohorts, and the diagnosis-to-treatment pathway loses patients between tissue-NGS or liquid-biopsy testing and the point first-line therapy actually starts, with turnaround time and guideline-complete testing rate the two levers that matter most for commercial modelling.

Sizing the wrong biomarker segment is the most common pre-launch NSCLC error.

Five questions this report answers:

Q1 - How does NSCLC segment by histology and actionable biomarker, and what governs treatment choice in each?

Q2 - How many patients present early enough for that segmentation to matter?

Q3 - What share of NSCLC actually carries each actionable biomarker?

Q4 - Which US centers and trial networks define practice and generate the evidence base?

Q5 - Where does the diagnosis-to-treatment pathway lose patients, and how fast does it move?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#NSCLC #LungCancer #Biomarkers #PrecisionOncology #DiseaseLandscape #USMarket

Live report page:  https://axlrx.ai/nsclc/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-                    hello@axlrx.ai

Web-                    https://axlrx.ai/

Myasthenia gravis is stratified by antibody subtype, not severity; only the roughly 85% of US patients who are AChR-positive can access C5 inhibitors.

Myasthenia gravis is an autoantibody-mediated disorder of the neuromuscular junction. Antibodies against the acetylcholine receptor, muscle-specific kinase, or LRP4 disrupt signal transmission and produce fluctuating, fatigable weakness. US prevalence is estimated at 100,000 to 200,000 patients, with recognised underdiagnosis. The population divides by serology: roughly 85% are AChR-antibody positive, about 5% MuSK-antibody positive, around 2% LRP4-positive, and 8 to 10% seronegative. Because AChR-mediated disease is complement-driven at the nerve-muscle junction, the C5 inhibitor class is approved only in the AChR-positive subgroup, making serology the commercial gate as much as the clinical one.

Severity is defined by the myasthenic crisis: respiratory failure requiring intubation and ICU support. An estimated 15% to 20% of patients experience at least one crisis in their lifetime, most often triggered by infection, with roughly 4% mortality per episode. Historical series show a median of about 13 days to extubation, with older age and low post-intubation vital capacity predicting a longer ventilator stay. The outstanding evidence gap is comparative effectiveness: which patients benefit most from FcRn blockade, complement inhibition, or traditional immunosuppression remains unresolved.

Antibody serology, not symptom severity, decides who can access which drug class.

Five questions this report answers:

Q1 - What is the AChR / MuSK / LRP4 / seronegative split of US gMG patients?

Q2 - How common and how dangerous is a myasthenic crisis in gMG patients?

Q3 - Where does misdiagnosis concentrate along the US gMG diagnostic pathway?

Q4 - What share of US myasthenia gravis patients are AChR-antibody positive?

Q5 - What triggers a myasthenic crisis, and how often is it fatal?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#MyastheniaGravis #gMG #Neurology #RareDisease #USHealthcare #Autoimmune

Live report page:  https://axlrx.ai/myasthenia-gravis/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-                    hello@axlrx.ai

Web-                    https://axlrx.ai/

Efgartigimod's June 2025 NICE rejection (TA1069) leaves roughly 4,000 UK generalised MG patients without a recommended novel agent.

Myasthenia gravis is an autoimmune disorder of the neuromuscular junction, most commonly driven by AChR antibodies in 85% of generalised MG, with anti-MuSK and anti-LRP4 subtypes accounting for the remainder. An estimated 7,000-10,000 UK patients have generalised MG; diagnosis is confirmed via AChR-Ab testing at routine NHS immunology labs available at every NHS trust, with anti-MuSK and anti-LRP4 testing reserved for specialist neuromuscular labs. The NHS neuromuscular network comprises approximately 30 specialist centres coordinated through the Muscular Dystrophy UK network, and the Myasthenia Gravis Association UK maintains a patient registry of roughly 3,000 enrolled members.

Eculizumab's own MG appraisal (TA636) was terminated in 2020 after the manufacturer chose not to submit a cost-effectiveness dossier, so NICE never modelled a cost-per-QALY figure for eculizumab in MG. Efgartigimod's appraisal concluded with final guidance TA1069, published 4 June 2025: NICE does not recommend efgartigimod for NHS use, citing gaps and uncertainties in the cost-effectiveness evidence. As a result, an estimated 4,000 UK moderate-to-severe gMG patients remain on the pyridostigmine plus corticosteroid, azathioprine, or mycophenolate backbone, with IVIg or plasma exchange reserved for crises. MGA UK survey data estimate that 30-40% of UK gMG patients have inadequate disease control on current standard therapy.

No novel agent has cleared NICE, leaving inadequate control unresolved for many patients.

Five questions this report answers:

Q1 - What is the size of the UK gMG population with inadequate control after TA1069's rejection?

Q2 - What is the NHS diagnostic pathway for MG, including thymoma screening and thymectomy eligibility?

Q3 - Why was eculizumab's MG appraisal withdrawn, and what does efgartigimod's TA1069 rejection mean next?

Q4 - How many UK patients does the Myasthenia Gravis Association's registry currently enrol?

Q5 - What share of AChR-positive cases account for generalised myasthenia gravis in the UK?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#MyastheniaGravis #NICE #NHS #UK #RareDisease #DiseaseLandscape

Live report page:  https://axlrx.ai/myasthenia-gravis/uk/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-                    hello@axlrx.ai

Web-                    https://axlrx.ai/

Just 8-10 GCC neurologists manage 70-80% of confirmed myasthenia gravis, yet 30-40% are first misdiagnosed as thyroid myopathy.

Myasthenia gravis affects an estimated 6,000 to 10,000 patients across the GCC, or 14 to 20 per 100,000, diagnosed via acetylcholine receptor antibody testing available at specialist neurology and immunology laboratories including KFSH&RC, AUH, Hamad Medical Corporation, and SKMC. The region's high background prevalence of thyroid disease creates a significant diagnostic confounder: thyroid eye disease and thyroid myopathy produce similar ptosis and fatigable weakness, and an estimated 30% to 40% of GCC MG patients are misdiagnosed as thyroid myopathy at first presentation, a distinctly GCC-shaped diagnostic trap rarely emphasised in Western literature.

That diagnostic delay has clinical consequences: GCC case series show 60% to 70% of patients present at MGFA Class III to IV, moderate-severe oculobulbar and limb weakness, versus approximately 40% in European series, with myasthenic crisis occurring at a higher proportion, tied to delayed diagnosis and late immunosuppressive therapy. Thymoma, present in 10% to 15% of MG patients, is worked up in most tertiary GCC referrals but not routinely elsewhere, and thymectomy capacity for non-thymoma cases remains limited. The concentration is stark: an estimated 8 to 10 neurologists across KSA, UAE, and Qatar tertiary centres manage 70% to 80% of all confirmed GCC generalised MG.

A thyroid look-alike hides myasthenia gravis until disease is already advanced.

Five questions this report answers:

Q1 - How does the thyroid-disease diagnostic confounder shape GCC MG time-to-diagnosis?

Q2 - Which 8-10 GCC neurologists manage most confirmed generalised MG, and what does concentration mean commercially?

Q3 - What is the NPHC/MOH formulary trajectory for efgartigimod against the pyridostigmine-plus-steroid backbone?

Q4 - What diagnostic and access barriers define the addressable GCC myasthenia gravis market?

Q5 - How often does thymoma occur in MG patients, and where is it worked up in the GCC?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#MyastheniaGravis #Neurology #FcRn #GCCHealthcare #DiseaseLandscape

Live report page:  https://axlrx.ai/myasthenia-gravis/gcc/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-           hello@axlrx.ai

Web-           https://axlrx.ai/

US MASH's commercial pool is not the 86.3 million with fatty liver; it is the 6.7 million with F2-F3 fibrosis, and most are unstaged.

MASH is the progressive, inflammatory form of fatty liver disease in which fat accumulation drives liver injury and fibrosis, renamed from NASH under the 2023 multi-society consensus. It sits inside a wide funnel: 86.3 million US adults have fatty liver disease, 14.9 million have MASH, and 6.7 million have MASH with clinically significant fibrosis, the FDA label-eligible pool, projected to rise to 11.7 million by 2050. Fibrosis stage, not the amount of fat in the liver, is what tracks with liver-related outcomes, so the treatable population is defined by staging rather than by the underlying disease's full size.

Fibrosis is graded from F0 to F4, and the treatable band sits at F2, significant, to F3, advanced but not yet cirrhosis; compensated cirrhosis is excluded from both approved agents and is what the next wave of pipeline drugs is chasing. The real constraint, though, is diagnosis, not disease size: most of the 6.7 million eligible patients are undiagnosed or unstaged in primary care. The standard pathway uses a blood test called FIB-4 to sort patients, then refers anyone in the indeterminate range to an elastography scan. Where that referral does not happen, eligible patients never reach a labeled therapy at all.

Diagnosis, not drug efficacy, is the real bottleneck in the US MASH market.

Five questions this report answers:

Q1 - How large is the US F2-F3 label-eligible MASH pool today?

Q2 - How is at-risk MASH staged without a liver biopsy in practice?

Q3 - Which MASH patients fall outside the label boundary entirely?

Q4 - How many US adults are actually eligible for MASH drug treatment?

Q5 - What FIB-4 and elastography thresholds gate a MASH diagnosis?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#MASH #FattyLiverDisease #Hepatology #Rezdiffra #USHealthcare #DiseaseLandscape

Live report page:  https://axlrx.ai/mash/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-           hello@axlrx.ai

Web-           https://axlrx.ai/